Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations

被引:118
作者
Soussi, T
Kato, S
Levy, PP
Ishioka, C
机构
[1] Univ Paris 06, Hop Tenon, Lab Genotoxicol Tumeurs, Dept Pneumol,EA3493,IC, F-75019 Paris, France
[2] Tohoku Univ, Dept Clin Oncol, Inst Dev Aging & Canc, Sendai, Miyagi 980, Japan
[3] Hop Tenon, Unite Biostat & Informat Med, INSERM, U444, F-75970 Paris, France
关键词
TP53; cancer; functional analysis; Li-Fraumeni; trans activation; database;
D O I
10.1002/humu.20114
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
TP53 alteration is the most frequent genetic alteration found in human cancers. To date, more than 15,000 tumors with TP53 mutations have been published, leading to the description of more than 1,500 different TP53 mutants (http://p53.curie.fr). The frequency of these mutants is highly heterogeneous, with 11 hotspot mutants found more than 100 times, whereas 306 mutants have been reported only once. So far, little is known concerning the biological significance of these rare mutants, as the majority of biological studies have focused on classic hotspot mutants. In order to gain a deeper knowledge about the significance of all of these mutants, we have cross,checked each mutant of the TP53 mutation database for its activity, derived from a library of 2,314 TP53 mutants representing all possible amino acid substitutions caused by a point mutation. The transactivation activity of all of these mutant was analyzed with respect to eight transcription promoters [Kato S, et al., Proc Natl Acad Sci USA (2003)100:8424-8429]. Although the most frequent TP53 mutants sustain a clear loss of transactivation activity, more than 50% of the rare TP53 mutants display significant activity. Analysis in specific types of cancer or in normal skin patches demonstrates a similar distribution of TP53 loss of activity, with the exception of melanoma, in which the majority of TP53 mutants display significant activity. Our data indicate that TP53 mutants represent a highly heterogeneous population with a large diversity in terms of loss of transactivation activity that could account for the heterogeneous tumor phenotypes and the difficulty of clinical studies. (C) 2004 Wiley Liss, Inc.
引用
收藏
页码:6 / 17
页数:12
相关论文
共 50 条
[1]   Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73 [J].
Bensaad, K ;
Le Bras, M ;
Unsal, K ;
Strano, S ;
Blandino, G ;
Tominaga, O ;
Rouillard, D ;
Soussi, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (12) :10546-10555
[2]   Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene [J].
Bougeard, G ;
Brugières, L ;
Chompret, A ;
Gesta, P ;
Charbonnier, F ;
Valent, A ;
Martin, C ;
Raux, G ;
Feunteun, J ;
Bressac-de Paillerets, B ;
Frébourg, T .
ONCOGENE, 2003, 22 (06) :840-846
[3]  
Brash DE, 1998, CANCER SURV, V32, P69
[4]   Rescuing the function of mutant p53 [J].
Bullock, AN ;
Fersht, A .
NATURE REVIEWS CANCER, 2001, 1 (01) :68-76
[5]   p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements [J].
Campomenosi, P ;
Monti, P ;
Aprile, A ;
Abbondandolo, A ;
Frebourg, T ;
Gold, B ;
Crook, T ;
Inga, A ;
Resnick, MA ;
Iggo, R ;
Fronza, G .
ONCOGENE, 2001, 20 (27) :3573-3579
[6]  
Cottu PH, 1996, ONCOGENE, V13, P2727
[7]   A novel mechanism of tumorigenesis involving pH- dependent destabilization of a mutant p53 tetramer [J].
DiGiammarino, EL ;
Lee, AS ;
Cadwell, C ;
Zhang, WX ;
Bothner, B ;
Ribeiro, RC ;
Zambetti, G ;
Kriwacki, RW .
NATURE STRUCTURAL BIOLOGY, 2002, 9 (01) :12-16
[8]   GAIN OF FUNCTION MUTATIONS IN P53 [J].
DITTMER, D ;
PATI, S ;
ZAMBETTI, G ;
CHU, S ;
TERESKY, AK ;
MOORE, M ;
FINLAY, C ;
LEVINE, AJ .
NATURE GENETICS, 1993, 4 (01) :42-46
[9]   DEFINITION OF A CONSENSUS BINDING-SITE FOR P53 [J].
ELDEIRY, WS ;
KERN, SE ;
PIETENPOL, JA ;
KINZLER, KW ;
VOGELSTEIN, B .
NATURE GENETICS, 1992, 1 (01) :45-49
[10]   Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast [J].
Flaman, JM ;
Robert, V ;
Lenglet, S ;
Moreau, V ;
Iggo, R ;
Frebourg, T .
ONCOGENE, 1998, 16 (10) :1369-1372